EWTX — Edgewise Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.50bn
- $1.94bn
- 52
- 24
- 93
- 58
Annual cashflow statement for Edgewise Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -17.1 | -42.8 | -67.6 | -100 | -134 |
| Depreciation | |||||
| Non-Cash Items | 0.354 | 4.4 | 10.6 | 8.22 | 12.4 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.95 | 4.63 | 4.09 | -1.56 | 10.3 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -14.6 | -33.5 | -52.6 | -91.9 | -109 |
| Capital Expenditures | -0.203 | -0.668 | -5.55 | -5.75 | -1.31 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -24.2 | -242 | -65 | 109 | -183 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -24.4 | -242 | -70.6 | 103 | -185 |
| Financing Cash Flow Items | — | 0.124 | 0.069 | 0.431 | 0.626 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 120 | 186 | 130 | 53.2 | 249 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 81.3 | -89.3 | 6.43 | 64.1 | -44.4 |